The authors report on 30 men treated with in-bore focal laser ablation (FLA) of clinically
localized prostate cancer. This data adds to this center's previously reported 2-year
early oncologic outcomes noting a 28% local recurrence rate of grade group ≥2, no
metastasis or deaths.
1
At 5 years, the authors report 83% failure-free survival (FFS) defined by lack of
salvage whole gland, systemic treatment, metastasis or prostate cancer death. In-field
tumor persistence was identified in 50% of men, and 60% of these cases were managed
with salvage focal ablation and one-third with whole gland therapy. Importantly, at
8 years follow-up, over 80% of men avoided whole gland therapy despite high in-field
recurrence.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to UrologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Two-year outcomes following focal laser ablation of localized prostate cancer.Eur Urol Oncol. 2018; 1: 129-133
- Image guided focal therapy for magnetic resonance imaging visible prostate cancer: defining a 3-dimensional treatment margin based on magnetic resonance imaging histology co-registration analysis.J Urol. 2015; 194: 364-370
- Magnetic resonance imaging underestimation of prostate cancer geometry: use of patient specific molds to correlate images with whole mount pathology.J Urol. 2017; 197: 320-326
Article info
Identification
Copyright
© 2021 Published by Elsevier Inc.
